10x Genomics and Curio Bioscience have reached a settlement over a patent infringement lawsuit concerning genomic technology patents initially filed by Prognosys Biosciences. This legal dispute, in which 10x Genomics held licensing rights, was resolved shortly before the case was set to go to trial, reflecting a growing trend in biotech companies to settle such matters outside the courtroom.
The lawsuit accused Curio Bioscience of infringing on patents related to genomics technology. The specifics of the settlement were not disclosed, but the agreement allows both companies to avoid a potentially protracted and costly legal battle. This resolution was announced by 10x Genomics on May 8, 2026, following weeks of negotiations between the parties involved. More on this development can be found in the report by Law360.
This settlement is considered significant within the field, reflecting a strategic decision by both companies to focus on innovation rather than litigation. Biotech firms often face the challenge of navigating intricate patent landscapes, with many opting to secure licensing agreements or settle disputes to maintain focus on research and development.
Such settlements highlight the importance of patent strategy in the competitive biotech industry. This particular case adds to a pattern where companies choose to settle disputes amicably, potentially setting precedents for how similar cases might be handled in the future. As Reuters notes, this agreement might encourage other tech firms to seek mutually beneficial resolutions to complex intellectual property challenges.